China’s New GCP Raises the Standard – Imaging Endpoints Was Already There

China’s revised Good Clinical Practice regulation does more than update clinical trial requirements. It extends the regulatory spotlight across the specialized service providers whose work contributes to critical trial data – including imaging CROs (iCROs).

Effective September 1, 2026, China’s revised GCP, issued under Announcement No. 50 of 2026, represents a meaningful advancement in clinical trial oversight. By incorporating principles from ICH E6(R3), the regulation reinforces the global movement toward risk-based quality management, stronger sponsor oversight, and reliable, submission-ready data.

These expectations are particularly important in imaging-intensive trials. Imaging data frequently supports endpoint determination and, ultimately, regulatory decisions concerning the efficacy of new therapies. The quality, traceability, and reliability of that data cannot depend on where a study is conducted or on which service provider processes it.

At Imaging Endpoints, this principle has long been embedded in our global operating model: imaging data must be managed with the same rigor, scientific expertise, and regulatory discipline expected of any critical clinical trial submission data.

As China strengthens its GCP framework, selecting an iCRO primarily on price without equivalent scrutiny of its quality systems, scientific capabilities, inspection readiness, and regulatory track record – will present increasing risk for sponsors.

The direction of travel is clear: increasingly harmonized global requirements will favor iCROs that can demonstrate quality and regulatory success across the globe – not merely promise low fees.

Imaging Endpoints has supported more than 200 successful marketing authorizations in oncology while maintaining a perfect inspection record. China’s revised GCP does not require us to reinvent our approach. It validates the quality-first model we have followed all along.

For more information,